Marley Kayden points to "Merger Monday" headlines in the biotech space as AstraZeneca (AZN) and Bristol Myers Squibb (BMY) could reportedly merge into a mega-company worth more than $400B. Sam Vadas looks overseas at the joint U.S.-Japan intervention on the yen currency. For tomorrow, Marley has her eyes on SpaceX (SPCX) earnings and Sam circles macro-data on her calendar including JOLTS with a first glimpse at July jobs data.